Yarrow Bioscience (NASDAQ:YARW – Get Free Report) and Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.
Institutional and Insider Ownership
83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Yarrow Bioscience and Zenas BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
| Zenas BioPharma | N/A | -144.65% | -59.83% |
Valuation and Earnings
This table compares Yarrow Bioscience and Zenas BioPharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yarrow Bioscience | $570,000.00 | 86.96 | -$26.48 million | ($14.64) | -1.27 |
| Zenas BioPharma | $10.00 million | 193.61 | -$377.74 million | ($9.42) | -3.03 |
Yarrow Bioscience has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Yarrow Bioscience has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Yarrow Bioscience and Zenas BioPharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yarrow Bioscience | 1 | 0 | 3 | 0 | 2.50 |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
Yarrow Bioscience currently has a consensus price target of $59.00, indicating a potential upside of 217.80%. Zenas BioPharma has a consensus price target of $46.71, indicating a potential upside of 63.64%. Given Yarrow Bioscience’s higher possible upside, equities research analysts clearly believe Yarrow Bioscience is more favorable than Zenas BioPharma.
Summary
Zenas BioPharma beats Yarrow Bioscience on 8 of the 14 factors compared between the two stocks.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.
Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
